The "legacy" of the $59 billion acquisition continues as Takeda embarks on a new round of "slimming"

Last year, Takeda completed its $59 billion acquisition of Shire.
the huge merger has led to a restructuring of the company, which continues to this day, even hurting Takeda's local operations in Japan.
August 18, Takeda announced that it would provide "early retirement" services to Japanese employees.
so-called "future career plan" will be aimed at sales and administration, but not the research and development or manufacturing business, according to the Nikkei Asian Review.
under the age of 30 who have been with the company for at least three years can apply for separation between September 28 and October 16, with the target departure date set for November 30.
who leave early will receive severance pay and support for finding a new job.
the company did not disclose the number of eligible employees.
but as of March 31 this year, Takeda had 47,495 employees globally, 6,509 of whom were from Japan.
," Mr. Takeda hinted in July that there would be organizational changes to try to move away from Japan's traditional tenure.
this time, Takeda said publicly: "We began to move to a personnel system aimed at improving the organizational capacity to support change, and this decision was made to import the "fusher carea process" for early retirement and transfer of employees as part of our response."
first announced its merger with Shire in 2018, Takeda said it expected to cut 6 to 7 per cent of its workforce, or about 3,600 people, to meet its initial annual cost-cutting target of $1.4bn.
this year, the company has increased its target to $2.3 billion, including the impact of COVID-19 on the global economy.
's previous corporate goal is to approve 31 new drugs in Japan by 2024, including new molecules and global brands that have already been approved for sale outside Japan.
During the recent decline in wage costs in Japan, Takeda plans to focus on innovative pharmaceutical products and develop five key business areas, namely gastrointestinal, rare diseases, oncology, neuroscience and plasma therapy.
, Takeda transferred 170 medical representatives from the Primary Health Care Department to the Oncology Department and 50 from the Department of Neuroscience in April this year.
said in July that it had decided to continue to streamline and restructure its medical team as new products and their candidates progressed.
the same time, the company is rumoured to be planning to spin off its Japanese consumer health division against the backdrop of Takeda's new focus area and $10bn divestiture target.
has been identified as a major competitor to local OTC giant Taisho Pharmaceuticals, which could be valued at more than $3bn, Bloomberg reported earlier.
.